Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXP) posted its earnings results on Tuesday. The company reported ($9.77) earnings per share for the quarter, missing the consensus estimate of ($6.23) by ($3.54), Zacks reports. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%.

Tonix Pharmaceuticals Trading Up 26.1 %

NASDAQ:TNXP traded up $4.25 during mid-day trading on Tuesday, reaching $20.53. The company’s stock had a trading volume of 2,551,960 shares, compared to its average volume of 625,484. The company’s fifty day simple moving average is $19.04 and its two-hundred day simple moving average is $19.79. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. Tonix Pharmaceuticals has a twelve month low of $6.76 and a twelve month high of $1,193.28. The stock has a market cap of $38.37 million, a P/E ratio of 0.00 and a beta of 2.23.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research note on Monday, February 10th. They set a “sell” rating on the stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.